Radotinib - an improvement on Nilotinib?
 

A recent post on the SoPD blog discusses radotinib, a promising BCR-ABL inhibitor that is currently in Phase III testing for chronic myeloid leukemia.

The focus of the blog post is the preclinical research on radotinib for PD (i.e. radotinib has yet to enter clinical trials for PD).

Is Radotinib ABL to beat Nilotinib? | The Science of Parkinson's

Thanks jeffreyn.

I am very impressed with SoPD.

I think that it discusses research in a way which is clear and accessible to people without relevant professional backgrounds.